Multicentre Isradipine Dose-Confirmation Study in Thai Patients With Hypertension
Isradipine is a new calcium antagonist of the dihydropyridine type, with marked vasodilator activity and minimum negative inotropic effects. It is a potent antihypertensive drug when given as monotherapy. This was a single-blind multicentre study consisting of 2 weeks’ placebo pretreatment and 8 wee...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Published: |
2018
|
| Subjects: | |
| Online Access: | https://repository.li.mahidol.ac.th/handle/123456789/16164 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Institution: | Mahidol University |
| Summary: | Isradipine is a new calcium antagonist of the dihydropyridine type, with marked vasodilator activity and minimum negative inotropic effects. It is a potent antihypertensive drug when given as monotherapy. This was a single-blind multicentre study consisting of 2 weeks’ placebo pretreatment and 8 weeks’ treatment with isradipine. After the placebo period, 90 patients aged 36 to 65 (mean 52) years with mild to moderate hypertension and diastolic blood pressures (DBPs) of > 95 to 114mm Hg, were started on isradipine 1.25mg twice daily for 4 weeks. The dosage for the next 4 weeks was increased to 2.5mg twice daily if the DBP was > 90mm Hg. At the end of the study 72 of 90 patients (80%) had achieved a reduction in DBP ⩾ 10mm Hg and, of these, 48 (53%) had DBPs of ⩽ 90mm Hg. This study confirms that isradipine 2.5mg twice daily is effective and well tolerated in the treatment of Thai patients with mild to moderate essential hypertension. © 1990, Adis International Limited. All rights reserved. |
|---|